These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22022385)

  • 1. EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells--a new option for the treatment of B-CLL.
    Ruiss R; Jochum S; Mocikat R; Hammerschmidt W; Zeidler R
    PLoS One; 2011; 6(10):e25294. PubMed ID: 22022385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
    Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
    Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
    Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
    Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro.
    Vallhov H; Gutzeit C; Johansson SM; Nagy N; Paul M; Li Q; Friend S; George TC; Klein E; Scheynius A; Gabrielsson S
    J Immunol; 2011 Jan; 186(1):73-82. PubMed ID: 21106852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.
    Cui X; Cao Z; Sen G; Chattopadhyay G; Fuller DH; Fuller JT; Snapper DM; Snow AL; Mond JJ; Snapper CM
    Vaccine; 2013 Jun; 31(30):3039-45. PubMed ID: 23665339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.
    Khyatti M; Patel PC; Stefanescu I; Menezes J
    J Virol; 1991 Feb; 65(2):996-1001. PubMed ID: 1846213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
    Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
    Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
    Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
    Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential of gene transfer into primary B-CLL cells using recombinant virus vectors.
    Wendtner CM; Kofler DM; Mayr C; Bund D; Hallek M
    Leuk Lymphoma; 2004 May; 45(5):897-904. PubMed ID: 15291346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40 activation: potential for specific immunotherapy in B-CLL.
    von Bergwelt-Baildon M; Maecker B; Schultze J; Gribben JG
    Ann Oncol; 2004 Jun; 15(6):853-7. PubMed ID: 15151939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells.
    Smith NA; Coleman CB; Gewurz BE; Rochford R
    J Virol; 2020 May; 94(11):. PubMed ID: 32238579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
    Busse C; Feederle R; Schnölzer M; Behrends U; Mautner J; Delecluse HJ
    J Virol; 2010 Jan; 84(2):1139-47. PubMed ID: 19889766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL.
    Gärtner K; Luckner M; Wanner G; Zeidler R
    J Extracell Vesicles; 2019; 8(1):1573051. PubMed ID: 30788083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation.
    Bejarano MT; Masucci MG; Morgan A; Morein B; Klein G; Klein E
    J Virol; 1990 Mar; 64(3):1398-401. PubMed ID: 2154620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
    Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
    J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.
    Pascutti MF; Jak M; Tromp JM; Derks IA; Remmerswaal EB; Thijssen R; van Attekum MH; van Bochove GG; Luijks DM; Pals ST; van Lier RA; Kater AP; van Oers MH; Eldering E
    Blood; 2013 Oct; 122(17):3010-9. PubMed ID: 24014238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell polyclonal activation and Epstein-Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis.
    Al Tabaa Y; Tuaillon E; Jeziorski E; Ouedraogo DE; Bolloré K; Rubbo PA; Foulongne V; Rodière M; Vendrell JP
    J Clin Virol; 2011 Sep; 52(1):33-7. PubMed ID: 21684200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
    Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
    Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia.
    Rasul E; Salamon D; Nagy N; Leveau B; Banati F; Szenthe K; Koroknai A; Minarovits J; Klein G; Klein E
    PLoS One; 2014; 9(8):e106008. PubMed ID: 25162594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.